
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics Inc, a clinical-stage biotechnology company specializing in dermatology and wound care, benefits from its proprietary PermaFusion technology, which enhances drug performance and aligns with market expectations for chronic inflammatory dermatologic conditions. The company's lead drug candidate, GX-03/Hexagen, targets the significant U.S. eczema market of approximately 16.5 million patients, positioning Turn for substantial revenue opportunities as it pursues commercialization pathways. Additionally, the successful advancement of its assets is bolstered by favorable reimbursement dynamics and the potential for strategic partnerships with larger players in the dermatology sector.
Bears say
Turn Therapeutics Inc faces a challenging financial outlook due to its dependency on milestone-based funding structures, which limit immediate capital availability and create potential future overhangs that could suppress stock performance. The company's focus on under-treated conditions, such as onychomycosis, reveals a market characterized by low treatment penetration, high recurrence rates, and modest cure rates, leading to ongoing patient challenges and limited revenue generation opportunities. Additionally, the inherent volatility and investment risks associated with small-cap biotechnology firms further contribute to a cautious perspective on Turn Therapeutics's stock.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares